NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma - (ProxiMMity-1)
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma
NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Patients Myeloma
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
NCT04855929: Phase 1: Safety and Therapeutic Activity of ANV419 in RRMM - ANV419-001
NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in RRMM
NCT04674813: Phase 1 - A Study of CC-95266 in Subjects With Relapsed and/or Refractory Myeloma
NCT04570631: Phase 1: Eftozanermin Alfa (ABBV-621) + Bortezomib and Oral Dexamethasone RRMM
NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04634435: Phase 1/2: Auto Memory-like NK Cell + BHV-1100 (Formerly KP1237), Low Dose IL-2 in NDMM
NCT04555551:Phase 1 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for Multiple Myeloma
NCT04093596: Phase 1 - ALLO-715 BCMA Allogenic CAR T Cells in relapsed Multiple Myeloma (UNIVERSAL)
NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma